Type 2 Diabetes Mellitus
Conditions
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes patients, aged 18-80 years (inclusive), who can continue to see doctors regularly (= 3 times a year); 2. Sign the informed consent voluntarily; 3. Patients who can cooperate with the'in-person Remote' Holonomic Diabetes Self-Management Support model management;
Exclusion criteria
Exclusion criteria: 1. Failure of important organs or other serious diseases, including patients with myocardial infarction, severe mental disorder, severe infection or disseminated intravascular coagulation within 12 months before enrollment; 2. Patients with active or inactive malignant tumors with life expectancy less than 1 year; 3. Patients who have communication barriers and cannot fully understand or cooperate; 4. Patients who have received remote management from other APPs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MACE incidence of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, revascularization, heart failure and nonfatal stroke); | — |
Secondary
| Measure | Time frame |
|---|---|
| Annual changes from baseline HbA1c and its in target rate;Annual changes from baseline BP and its in target rate;Annual changes from baseline LDL-c and its in target rate;Annual changes from baseline BMI and its in target rate;Annual change from the baseline on self-management behavior scale score;Annual change from baseline on self-efficacy scale score;Annual change from baseline on A-DQOL score;Annual changes in Morisky medication compliance score scale compared with the baseline;Annual change from baseline on DASS-21 score;Patient satisfaction score;Incidence of new onset diabetes nephropathy;Incidence of retinopathy in newly diagnosed diabetes;Incidence of new onset diabetes neuropathy;Incidence of new onset diabetes related lower extremity arterial disease;Incidence of newly diagnosed diabetes foot;Progression of albuminuria;Progression of diabetes retinopathy;Progression of lower extremity arterial disease in diabetes;Progression of diabetes foot;Incidence of hospitalization due to major infections/acute complications;Incidence of malignant tumors;Incidence rate of all-cause death;Long term cost-effectiveness of 'in-person Remote' Holonomic Diabetes Self-Management Support model;HbA1c in target rate (<7%);BP in target rate(<130/80 mmHg);LDL-c in target rate(<2.6 mmol/L); | — |
Countries
China
Contacts
Public ContactZhang Junqing and Li Ang
Peking University First Hospital
Outcome results
None listed